All companies
Visit website
Zenus, Inc.
OperatingHealthcare · Founded 2015
Video analysis on a massive scale
Post-money valuation ⓘ
$10.6M
As of Dec 2021 · from Zenus, Inc. Stock 1 · pre-money + amount raised, not a traded price
Total raised
$552,432
Across 1 round since 2020
Latest share price
$2.02
Zenus, Inc. Stock 1 offering price
Financials
FY2018–FY2024 · from SEC filings · hover any figure for its source$42K
−$386K
2018
$55K
−$419K
2019
$31K
−$226K
2020
$235K
−$465K
2022
$334K
−$1.5M
2023
$939K
−$1.3M
2024
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2018
FY2019
FY2020
FY2022
FY2023
FY2024
Income statement
Revenue
$41,893
$55,383
$31,321
$235,430
$334,396
$938,506
Cost of goods sold
$2,342
$7,850
$2,037
$29,748
$54,541
$195,194
Gross margin
94%
86%
93%
87%
84%
79%
Net income
-$385,766
-$419,282
-$226,495
-$464,517
-$1,477,174
-$1,269,257
Taxes paid
$0
$0
$0
$0
$620
$3,145
Balance sheet
Cash
$406,039
$217,701
$201,930
$1,315,882
$262,688
$559,284
Accounts receivable
$0
$10,144
$0
$198,782
$91,192
$162,583
Total assets
$406,039
$227,845
$201,930
$1,452,441
$476,100
$1,066,902
Short-term debt
$12,874
$8,963
$0
$0
$676,062
$636,879
Long-term debt
$0
$0
$20,300
$25,824
$0
$1,899,241
Total liabilities
$12,874
$8,963
$20,300
$25,824
$676,062
$2,536,120
Other
Headcount
—
4
4
—
7
8
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$10.6M
post-money
Zenus, Inc. Stock 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $552.4K / $1.1MInvestors 829Post-money $10.6M
Reg CF annual-report compliance
Not requiredFiled Form C-TR (terminated reporting)
Filed 3 of 6 annual reports (FY2020–FY2025)
829 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 11 filings on EDGARSource: ManualCIK 0001821125Share price $2.02
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.